title: Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma.
abstract: A chemotherapeutic protocol using carmustine in combination with vincristine and prednisone was tested in dogs with multicentric malignant lymphosarcoma. Of seven dogs treated, six (85.7%) achieved complete remission. A partial response occurred in one dog. Median survival time was 224 days (mean 386 days), and median duration of remission was 183 days (mean 323 days). Marked neutropenia was observed following carmustine administration. There were no significant alterations in platelets and red blood cell counts during treatment, and no abnormalities attributable to the chemotherapy were found in serum biochemical profiles. Results of this study showed that carmustine is an effective alternative option in the treatment of canine lymphosarcoma.
authors.affiliation: Faculdade de Medicina, Veterinária e Zootecnia, Universidade de São Paulo, Brazil.
authors.forename: Sílvia Regina
authors.initials: SR
authors.lastname: Ricci Lucas
authors.forename: Bruna Maria
authors.initials: BM
authors.lastname: Pereira Coelho
authors.forename: Maurício Luis
authors.initials: ML
authors.lastname: Marquezi
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Franchini
authors.forename: Samantha Ive
authors.initials: SI
authors.lastname: Miyashiro
authors.forename: Diana Helena
authors.initials: DH
authors.lastname: De Benedetto Pozzi
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001774:Blood Chemical Analysis / Q000662:veterinary; D002330:Carmustine / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004285:Dogs; D005260:Female; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D009503:Neutropenia / Q000139:chemically induced / Q000662:veterinary; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D014750:Vincristine; D002330:Carmustine; D011241:Prednisone